Zynerba Pharmaceuticals, Inc
ZYNE
ZYNE was delisted on the 10th of October, 2023.
66 hedge funds and large institutions have $77M invested in Zynerba Pharmaceuticals, Inc in 2017 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 19 increasing their positions, 15 reducing their positions, and 20 closing their positions.
30% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 20
27% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 15
10% more funds holding
Funds holding: 60 → 66 (+6)
9% more capital invested
Capital invested by funds: $70.5M → $77M (+$6.53M)
41% less call options, than puts
Call options by funds: $17.1M | Put options by funds: $28.8M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$9.17M |
| 2 |
JP Morgan Chase
New York
|
+$6.48M |
| 3 |
Mirae Asset Global Investments
Seoul,
South Korea
|
+$6.03M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$4.44M |
| 5 |
Citigroup
New York
|
+$4.38M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$10.1M |
| 2 |
PA
Perceptive Advisors
New York
|
-$5M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$2.01M |
| 4 |
MWA
Marshall Wace Asia
Central,
Hong Kong
|
-$1.65M |
| 5 |
MWNA
Marshall Wace North America
New York
|
-$1.51M |
ZYNE Hedge Fund Activity: Q2 2017 in Review
66 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Zynerba Pharmaceuticals, Inc (ZYNE) for Q2 2017, worth a combined $77M — up 9.3% from $70.5M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new ZYNE positions and 20 closed out — a net gain of 6 holders — while 19 added to existing stakes and 15 trimmed.
The largest buyer was BlackRock, adding an estimated $9.17M. The largest seller was Cormorant Asset Management, exiting entirely with an estimated $10.1M sold.
- 66 institutional investors held Zynerba Pharmaceuticals, Inc (ZYNE) as of Q2 2017, up from 60 in Q1 2017.
- Funds reported $77M of Zynerba Pharmaceuticals, Inc stock for Q2 2017, up 9.3% quarter-over-quarter.
- 26 funds opened new Zynerba Pharmaceuticals, Inc positions in Q2 2017 and 20 closed out, a net change of +6 holders.
- The largest Zynerba Pharmaceuticals, Inc buyer in Q2 2017 was BlackRock, an estimated $9.17M added.
- The largest Zynerba Pharmaceuticals, Inc seller in Q2 2017 was Cormorant Asset Management, an estimated $10.1M sold.
Based on aggregated 13F filings for Q2 2017.